This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

FTC may need to update studies on competitive effects of generic pharma mergers, Wright says

By Leah Nylen ( December 5, 2014, 20:37 GMT | Insight) -- The US Federal Trade Commission may need to update its economic studies on the impact of consolidation in the generic pharmaceutical market if the agency wants to continue to rely on them to justify requiring divestitures or blocking particular deals, the junior Republican commissioner said.The US Federal Trade Commission may need to update its economic studies on the impact of consolidation in the generic pharmaceutical market if the agency wants to continue to rely on them to justify requiring divestitures or blocking particular deals, the junior Republican commissioner said....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login